Successful PEGS Prompts SAW Instruments GmbH to Extend Sam®X Biosensor Access Program  
5/21/2012 9:12:27 AM

Bonn, Germany – 21 May 2012 – SAW Instruments, developer of the innovative sam® family of biosensors for real-time, label-free assays using viable cells, has revealed that it plans to extend its sam®X Biosensor Access Program until 31 May 2012 due to the large volume of interest in its systems during the recent Protein Engineering Summit (PEGS) in Boston, MA, USA. This included a “standing-room-only” talk by Dr Uwe Reusch, Head of Cell Culture at Affimed Therapeutics, which was attended by over 400 participants. They heard how a sam® system was used to generate accurate real-time binding data when Affimed’s TandAb bispecific antibodies were applied to viable, intact cancer cells. In response to customer interest, the slides from the talk are now available for download at the SAW website.

As the high-end member of the sam® family, the new sam®X features adaptable microfluidic routing and eight sensor channels, providing a flexible, higher-throughput option for studying binding kinetics of antibodies to receptors on intact living cells. The sam®X Biosensor Access Program offers a six month lease of the new system, with an option to purchase at the end of the trial. The promotion also includes four free packs of CM short dextran chips and four free days of application training worth $10,000.

Contact Ian Taylor ( before the 31st May 2012 deadline to find out how a sam®X system could revolutionise pre-clinical binding affinity studies in your laboratory, or visit to find out more.

Notes on the technology

Surface Acoustic Wave technology is based on the ability of a wave of energy to travel across the surface of a material. Each surface has a typical inherent elasticity affecting the way the energy of the wave dissipates as it travels across the surface of the material being analysed. Thus, the nature of the surface in question, and therefore any changes to it, can be assessed by sensors monitoring the behaviour of the wave as it propagates across the surface. In particular, changes in mass result in alterations to the phase of the wave, whilst viscoelastic and conformational characteristics influence wave amplitude. The technology developed and employed by SAW instruments is capable of accurately interpreting this information in order to provide real time readouts measuring binding and conformational changes in the samples through which the wave passes.

About SAW Instruments GmbH

SAW Instruments GmbH, headquartered in Bonn, Germany, designs, develops and sells biosensor-based laboratory instruments for life sciences research. The proprietary technology of SAW Instruments employs a Surface Acoustic Waves approach to biological measurement, rather than using traditional optical methods such as SPR. The technology is uniquely positioned compared to other biosensor technologies based on its ability to measure antibody binding to whole cells, protein small molecule binding in high DMSO, and conformational changes in proteins caused by ligand binding. In addition, the system is also capable of providing other industry standard measurements including those involving concentration, kinetics and affinity.

SAW instruments has more than ten years experience in the field of label-free biosensor technology and a number of our customers have successfully published work employing the platform. It is our goal is to continue to build on this experience, as well as to develop a family of workflow-driven products to further meet our customers’ needs.

About SAW Instruments USA, LLC

SAW Instruments USA, LLC is a wholly owned US subsidiary of SAW Instruments GmbH